Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Dec 4;3(12):e004157.
doi: 10.1136/bmjopen-2013-004157.

Evaluation of three-dose fosfomycin tromethamine in the treatment of patients with urinary tract infections: an uncontrolled, open-label, multicentre study

Lu-Dong Qiao  1 , Bo Zheng, Shan Chen, Yong Yang, Kai Zhang, Hong-Feng Guo, Bo Yang, Yuan-Jie Niu, Yi Wang, Ben-Kang Shi, Wei-Min Yang, Xiao-Kun Zhao, Xiao-Feng Gao, Ming Chen
Affiliations

Evaluation of three-dose fosfomycin tromethamine in the treatment of patients with urinary tract infections: an uncontrolled, open-label, multicentre study

Lu-Dong Qiao et al. BMJ Open. .

Abstract

Objective: To evaluate the clinical and microbiological efficacy and safety of three doses of 3 g fosfomycin tromethamine administered orally to treat lower urinary tract infections.

Design and participants: This prospective, uncontrolled, open-label study was conducted in 12 medical centres in China, between January and December 2011. According to the diagnosis criteria of Chinese Guidelines on Urological Infections, patients (18-70 years) with acute uncomplicated cystitis, recurrent lower urinary tract infection or complicated lower urinary tract infection received three doses of 3 g fosfomycin tromethamine orally, at days 1, 3 and 5.

Primary and secondary outcome measures: Efficacy endpoints (clinical efficacy, microbiological efficacy and overall efficacy) were evaluated on day 15. Clinical symptoms, physical signs, urinalysis, liver and kidney function, patient records and evaluation of adverse events (AEs) and serious AEs up to day 15 were evaluated for analysis of safety.

Results: 361 patients were included in the full analysis set, 356 in the safety analysis set and 335 in the per-protocol set (PPS). In the PPS, the clinical efficacy rates at day 15 for acute uncomplicated cystitis, recurrent lower urinary tract infection and complicated lower urinary tract infection were 94.71% (179/189), 77.22% (61/79) and 62.69% (42/67), respectively. The microbiological efficacy rates (day 15) were 97.65% (83/85), 94.44% (34/36) and 83.87% (26/31), respectively. The overall efficacy rates (day 15) were 95.29% (81/85), 77.78% (28/36) and 64.52% (20/31), respectively. 20/356 (5.6%) patients reported drug-related AEs, the most common being diarrhoea. No serious drug-related AEs were reported.

Conclusions: This fosfomycin tromethamine dosing regimen showed clinical and microbiological efficacy with some AEs and good tolerability in patients with acute uncomplicated cystitis, recurrent lower urinary tract infection and complicated lower urinary tract infection.

Keywords: Urology.

PubMed Disclaimer

References

    1. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 2002;113:5S–13S - PubMed
    1. Pinner RW, Teutsch SM, Simonsen L, et al. Trends in infectious disease mortality in the United States. JAMA 1996;275:189–93 - PubMed
    1. Wang JQ, Wu XP, Li YJ, et al. Nosocomial infection point-prevalence survey in three consecutive years. Chin J Infect Control 2006;01:19–34
    1. Wang JX, Zhu XL, Yang LY. A nosocomial infection point-prevalence survey: results and analysis. Chin J Nosocomiol 2005;10:1119–20
    1. Schito GC. Why fosfomycin trometamol as first line therapy for uncomplicated UTI? Int J Antimicrob Agents 2003;22:79–83 - PubMed

LinkOut - more resources